Results 31 to 40 of about 3,270 (204)
Infectious Diseases and Therapy, 2020 Introduction Outcomes data for patients who received tedizolid for acute bacterial skin and skin-structure infections (ABSSSIs) are scant. We provide a real-world analysis of economic and clinical outcomes following tedizolid use in the outpatient ...
Ravina Kullar +3 more
doaj +1 more source
Antibiotikaresistenzen gezielt überwinden [PDF]
, 2016 Neue Strategien zur Bekämpfung von Antibiotikaresistenzen zu finden, ist eine der grössten globalen Herausforderungen für die Gesundheitssysteme. In den letzten Jahrzehnten gab es eine drastische Zunahme an humanpathogenen Bakterien, die resistent gegen ...
Chellat, Mathieu F. +2 more
core +1 more source
Linezolid pharmacokinetics in MDR-TB : a systematic review, meta-analysis and Monte Carlo simulation [PDF]
, 2018 This work was supported by the Wellcome Trust (grant numbers 109129/Z/15/Z to JM and 105620/Z/14/Z to DS and MC).Objectives The oxazolidinone linezolid is an effective component of drug - resistant TB treatment, but use is limited by toxicity and the ...
Alffenaar, Jan-Willem C +11 more
core +5 more sources
In vitro activity of Tedizolid and Dalbavancin against MRSA strains is dependent on infection source
International Journal of Infectious Diseases, 2019 Objective: We tested the in vitro susceptibility to Tedizolid and Dalbavancin of Methicillin-resistant Staphylococcus aureus strains recovered from blood and wound cultures, and compared our results with studies conducted in the last four years.
Maya Azrad +4 more
doaj +1 more source
Comparing the cost-effectiveness of linezolid to trimethoprim/sulfamethoxazole plus rifampicin for the treatment of MRSA infection: a health-care system perspective [PDF]
, 2017 To date few industry-independent studies were conducted to compare the relative costs and benefits of drugs to treat MRSA infection. We performed a stochastic cost-effectiveness analysis comparing two treatment strategies -- linezolid versus trimethoprim-
Harbarth, S. +6 more
core +2 more sources
Biomédica: revista del Instituto Nacional de Salud, 2018 Introducción. Staphylococcus aureus resistente a meticilina (SARM) causa infecciones graves de la piel y los tejidos blandos en los hospitales y, en los últimos años, en la comunidad.
Aura Lucía Leal +9 more
doaj +1 more source
Targeting antibiotic resistance [PDF]
, 2016 Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.
Chellat, Mathieu F. +2 more
core +1 more source
Brazilian Journal of Infectious Diseases, 2017 Introduction: Treatment of multidrug-resistant Gram-positive infections caused by Staphylococcus aureus remains as a clinical challenge due to emergence of new resistance mechanisms.
Johanna Marcela Vanegas Múnera +3 more
doaj +1 more source
Advances in antibiotic therapy in the critically ill [PDF]
, 2016 Infections occur frequently in critically ill patients and their management can be challenging for various reasons, including delayed diagnosis, difficulties identifying causative microorganisms, and the high prevalence of antibiotic-resistant strains ...
Antonelli, Massimo +13 more
core +2 more sources
Tedizolid Population Pharmacokinetics, Exposure Response, and Target Attainment [PDF]
Antimicrobial Agents and Chemotherapy, 2014 ABSTRACT Tedizolid phosphate is a novel antibacterial prodrug that is rapidly and extensively converted to its active moiety, tedizolid. We developed a population pharmacokinetics (PK) model for tedizolid using pooled data from seven densely and sparsely sampled clinical trials evaluating oral and intravenous tedizolid.
S, Flanagan +5 more
openaire +2 more sources